Furthermore, there was a phase II clinical trial, NCT03430466, which added the ER antagonist fulvestun to the immunotherapy of tremelimumab and durvalumab in patients with HR+/HER2- breast cancer, but the trial was terminated for unknown reasons. Here, ESR1 is linked to breast carcinoma.